Guardian Pharmacy Recalls Lidocaine Syringes Due to Sterility Concerns
Guardian Pharmacy Services is recalling 250 syringes of Lidocaine 3% in Texas due to a lack of sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of sterility assurance, which poses a risk of serious injury or infection.
Plain-English summary
Guardian Pharmacy Services is recalling 250 10-mL syringes of Lidocaine 3% (Rx Only) in Texas. The recall was initiated because of a lack of sterility assurance for the compounded product.
The affected lots are 58641:42 (Use By: 06/04/2018), 58775:42 (Use By: 06/16/2018), and 59077:42 (Use By: 07/17/2018). The product was distributed in Texas.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Lidocaine 3% 10 ml. Rx Only. Packaged in 10 mL syringes. Compounded Guardian Pharmacy Services, 7920 Elmbrook Dr. Ste. 108C Dallas TX 75247
- Manufacturer
- Guardian Pharmacy Services
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: 58641:42 Use By: 06/04/2018
- 58775:42 Use By: 06/16/2018
- 59077:42 Use By: 07/17/2018
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 23 recalled by Guardian Pharmacy Services under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 23 products in this recall →Related recalls
Same manufacturer · Guardian Pharmacy Services
See all →- SevereGuardian Pharmacy Recalls Glutathione Vials Due to Sterility Concerns
FDA (Drugs) · 2018-08-15
- SevereGuardian Pharmacy Recalls Phenol 6% Injection Due to Sterility Concerns
FDA (Drugs) · 2018-08-15
- SevereGuardian Pharmacy Recalls Morphine Sulfate CADD Due to Sterility Concerns
FDA (Drugs) · 2018-08-15
- SevereGuardian Pharmacy Recalls Cefazolin Syringes Due to Sterility Concerns
FDA (Drugs) · 2018-08-15
- SevereGuardian Pharmacy Recalls Glycopyrrolate Syringes Due to Sterility Concerns
FDA (Drugs) · 2018-08-15
Same hazard · lack of sterility
See all →- SevereK.C. Pharmaceuticals Recalls Dry Eye Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Multiple Brands of Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
Similar recalls
- CriticalGuardian Pharmacy Recalls Lidocaine Syringes Due to Failed Sterility Test
FDA (Drugs) · 2016-12-28
- SeverePharmakon Recalls Lidocaine Syringes Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereVann Healthcare Recalls Lidocaine Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-31
- SevereAdvanced Pharma Recalls Lidocaine Syringes Due to Sterility Concerns
FDA (Drugs) · 2019-03-27
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- SevereUS Compounding Recalls Lidocaine Syringes Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-25